Baseline Bleeding Risk and Benefit of Transradial PCI Making Lemonade Out of Lemons∗ by Bertrand, Olivier F. & Rao, Sunil V.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 4 , N O . 1 5 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N CO L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 6 . 1 2 0 2EDITORIAL COMMENTBaseline Bleeding Risk and Beneﬁt
of Transradial PCI
Making Lemonade Out of Lemons*Olivier F. Bertrand, MD, PHD,y Sunil V. Rao, MDzA fundamental aspect of clinical trials is thequantitative interaction, whereby the high-est risk patients gain the most beneﬁt from
a therapeutic intervention. For bleeding avoidance
strategies, this means that the patients at greatest
risk for bleeding will beneﬁt the most from appro-
priate dosing of antithrombotic medications and
radial access. Although femoral access remains the
dominant approach for coronary angiography and
percutaneous coronary intervention (PCI), the radial
approach continues to gain popularity worldwide. In
the United States, data from the National Cardiovascu-
lar Data Registry (NCDR) indicated a rate for radial
approach usage of 1.8% in 2007; however, by mid-
2012, that rate had climbed to 17% (1,2). Evidence sug-
gests that this rate continues its rapid ascent.
Many factors may explain this renewed interest
in a technique ﬁrst described >20 years ago. Most
notably, despite little industry support, several large
randomized trials comparing the radial approach
with the femoral approach have shown clinical and
nonclinical beneﬁts and an overwhelming patient
preference favoring radial access (3). Second, obser-
vational data from very large national databases
have further allowed better characterization of use
and beneﬁts associated with a radial approach in
contemporary clinical practice (4).
Whereas important lessons have already been
learned from the United States based on NCDR data*Editorials published in the Journal of the American College of Cardiology
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and Angioplasty Registry data, only recently have
data from the large British Cardiovascular Inter-
vention Society (BCIS) database become available.
Although registry data suffer from well-known limi-
tations (e.g., confounding factors, selection bias),
they are nonetheless useful for evaluating everyday
practice by a wide representation of clinicians and
patients. Moreover, the large sample sizes support
sophisticated statistical techniques, such as pro-
pensity score adjustment, to overcome bias. Apart
from the strength of randomized allocation in a
context of a trial with speciﬁc inclusion and exclu-
sion criteria, this form of adjustment permits robust
outcome comparisons between 2 groups in a large
unselected population. Data from large databases
also allow for the evaluation of longitudinal changes,
which might be particularly important when tech-
nical aspects (e.g., radial approach) evolve over time.
Peri-procedural bleeding complications are now
recognized as independent predictors of worse out-
comes after femoral and radial PCI (5,6). In recent
literature, bleeding complications are split into access
site–related and nonaccess site–related bleeding (7,8).
It is widely accepted that the radial approach almost
completely eliminates access site bleeding. Although
in some cases, access site bleeding (e.g., retroperito-
neal bleeding) can be life-threatening, the more
detrimental impact of nonaccess site bleeding has
been carefully analyzed in a post-hoc analysis of
REPLACE-2 (Randomized Evaluation in PCI Linking
Angiomax to Reduced Clinical Events), ACUITY (Acute
Catheterization and Urgent Intervention Triage
Strategy), and HORIZONS-AMI (Harmonizing Out-
comes With Revascularization and Stents in Acute
Myocardial Infarction) trials (8). In this investigation,
nonaccess site bleeding was associated with a hazard
ratio (HR) of 3.94 for 1-year mortality compared with
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1566an HR of 1.82 for access site bleeding. The incidence
of access site and nonaccess site bleeding is
inﬂuenced by clinical scenarios and by antithrombotic
regimens. In general, the risk for bleeding increases
with higher risk patients, clinical scenarios, and
antithrombotic regimens (i.e., ST-segment elevation
myocardial infarction > non–ST-segment elevation
myocardial infarction > stable angina) (9). However,
the proportion of access site bleeding is highest
in patients with stable angina and ST-segment
elevation myocardial infarction (50% to 70%).SEE PAGE 1554In this issue of the Journal, Mamas et al. (10)
evaluated data from 348,689 PCI procedures from
patients entered into the BCIS database from 2006 to
2011 to determine the association between baseline
bleeding risk and the clinical impact of radial access.
The authors used in-hospital major bleeding compli-
cations deﬁned as intracerebral or gastrointestinal
bleeding, retroperitoneal hematoma, blood or platelet
transfusion, or arterial site complication requiring
surgery. Hence, this was a pure clinical bleeding
deﬁnition with no hemoglobin drop cutoff and always
an overt source of bleeding. To assess baseline
bleeding risk, the researchers modiﬁed the original
score developed by Mehran et al. (11) that used
clinical trial data of patients who underwent
transfemoral PCI exclusively. Furthermore, major
bleeding in the analysis by Mehran et al. (11) was
deﬁned according to Thrombolysis In Myocardial
Infarction (TIMI) major criteria. The score includes
mostly nonmodiﬁable factors (i.e., sex, age, baseline
serum creatinine and white blood cell count, smoking
status, clinical presentation) and 1 procedural
parameter (e.g., antithrombotic regimen). In brief, a
score of 10 predicted a risk of 30-day noncoronary
artery bypass graft surgery TIMI major bleeding
of <1%; a score of 20 predicted a risk of 3.1%; and a
score of 30 meant a risk of 9.5%. Most patients had a
score between 5 and 25. Of note, noncoronary artery
bypass graft surgery–related TIMI major bleeding
in this analysis was associated with an HR of 4.2
(95% conﬁdence interval [CI]: 3.1 to 5.7) for 1-year
mortality.
Using the modiﬁed Mehran score, Mamas et al. (10)
also evaluated 30-day all-cause mortality. In-
terestingly, baseline bleeding risk was not only a
strong independent predictor of in-hospital major
bleeding (each unit increase was associated with 10%
increased risk) but also 30-day mortality (each unit
increase was associated with 18% increased risk).
There was no interaction with access site, suggesting
that the model worked well independently of theaccess site choice. Importantly, compared with
femoral access, radial access was associated in both
the bleeding and mortality multivariable models with
a signiﬁcant reduction in both outcomes: an odds
ratio of 0.26 (95% CI: 0.22 to 0.31) for in-hospital
bleeding and an odds ratio of 0.82 (95% CI: 0.73 to
0.91) for 30-day mortality.
The authors also observed a “radial treatment
paradox”: speciﬁcally, radial access was used more
often inpatientswith lower baseline bleeding risk (43%
with amodiﬁed risk score<10 and 40%with amodiﬁed
risk score >20). This discrepancy has previously been
observed in the NCDR data, albeit with a much nar-
rower gap than in the BCIS database, presumably due
to the greater popularity of the radial approach in
the United Kingdom (12). This paradox is actually not
surprising considering that female sex and older age
(2 variables known to be associated with higher
bleeding risk) have been linked with more radial fail-
ures, especially during the operator learning curve (13).
Most importantly, using crude data or propensity-
matched cohorts, Mamas et al. (10) found an incre-
mental mortality beneﬁt with higher baseline
bleeding risk according to the modiﬁed risk score. The
higher the score, therefore, the bigger the beneﬁt for
radial access in terms of in-hospital bleeding and
30-day mortality.
These data, along with other studies delineating the
risk–treatment paradox related to bleeding avoidance
strategies, strongly support identifying a patient’s
bleeding risk pre-procedurally and consciously im-
plementing radial approaches in the patients when-
ever possible (12,14). Several clinical bleeding scores
are now available to guide physicians; all include
various nonmodiﬁable and modiﬁable parameters.
Because modiﬁable factors include access site, sheath
size, and anticoagulation therapy, radial access is an
integral part of providing high-quality PCI (15).
As data from clinical trials and everyday experi-
ence continue to accumulate demonstrating the
radial approach’s numerous advantages, it is now
time to work so that radial access becomes the
default site for diagnostic coronary angiography and
intervention. The recent abundance of radial courses
and radial forums within cardiology conferences and
congresses is a testimony to the importance of mod-
ern interventional cardiologists becoming proﬁcient
with transradial procedures.
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